Recce (ASX:RCE) share price surges 6% on clinical trial registration

The Recce Pharmaceuticals (ASX: RCE) share price is soaring today after the company announced positive progress on its Recce 327 compound.

| More on:
Rising healthcare ASX share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Recce Pharmaceuticals Ltd (ASX: RCE) shares are on the move in mid-afternoon trade. This comes after the company announced the inclusion of Recce 327 into the Australian New Zealand Clinical Trial Registry (ANZCTR).

At the time of writing, the Recce share price is swapping hands for $1.255, up 6.36%.

Checkpoint passed

The Recce share price is responding positively after the biotech company advised that its lead compound, Recce 327, has been registered in the ANZCTR for its phase I/II topical burns study in humans. The Recce 327 topical antibiotic therapy will seek to treat infected burn wounds in adults.

Established in 2005, ANZCTR is an online public registry of clinical trials being undertaken domestically and abroad. The purpose of the organisation is to improve research transparency, making all details of the trial publicly available. In addition, public awareness can facilitate increased trial participation, avoid duplication of similar studies, identify research areas, and promote collaboration.

ANZCTR consists of a variety of trials such as pharmaceuticals, surgical procedures, preventive measures, treatment and rehabilitation strategies, and more. Notably, registration with ANZCTR is one of the final administrative checkpoints for clinical trials to commence.

The upcoming phase I/II topical burns study will assess the safety and efficacy of Recce 327 from 30 recruits. Over 2 weeks, 10 patients will receive Recce 327 on a daily basis. The other remaining participants will receive the Recce 327 three times per week.

The company stated that it will update shareholders as the trial progresses.

Recce share price review

Recce is involved in the advancement of synthetic antibodies designed to address the global health challenge of antibiotic-resistant superbugs. The medical company's flagship drug, Recce 327 is being developed to treat blood infections and sepsis.

The group operates solely in research and development and is located in both Australia and the United States.

In the past 12 months, the Recce share price has stormed more than 280% higher and is around 15% up year to date. The company's shares hit a record high of $1.875 in August 2020 on the back of positive investor sentiment.

Based on the current share price, Recce has a market capitalisation of roughly $221.5 million, with 173.7 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »